Commercial Availability of Alpha-Emitting Radionuclides for Medicine

Journal Article · Mon Sep 15 00:00:00 EDT 2008 · Current Radiopharmaceuticals, 1(3):127-134

DOI:https://doi.org/10.2174/1874471010801030127· OSTI ID:949917

Fisher, Darrell R

Alpha-emitting radionuclides provide effective cell-killing properties and have been shown to be effective in cancer treatment. The number of different alpha emitters having suitable physical and chemical characteristics for applications in medicine is relatively few. Development and testing of new radiopharmaceuticals requires a reliable supply of alpha-emitters in high quality, with timely delivery, but at reasonable cost. Applications and commercial availability of the follow alpha emitters are reviewed: Actinium-225, bismuth-213, astatine-211, radium-223, bismuth-212, radium-224, radium-226, terbium-149, and thorium-227. Recommendations for improving the supply of these alpha emitters include an increased federal commitment (through funding and joint-agency cooperation), establishing new production capabilities, and strengthening federal-private partnerships with companies involved in helping to meet critical radionuclide supplies.

• Research Organization: Pacific Northwest National Lab. (PNNL), Richland, WA (United States)
• Sponsoring Organization: USDOE
• DOE Contract Number: AC05-76RL01830
• OSTI ID: 949917
• Report Number(s): PNNL-SA-59529; ST6001030; TRN: US0901919
• Journal Information: Current Radiopharmaceuticals, 1(3):127-134, Vol. 1, Issue 3
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
ACTINIUM 225
ASTATINE 211
AVAILABILITY
BISMUTH 212
BISMUTH 213
CELL KILLING
MEDICINE
NEOPLASMS
PRODUCTION
RADIOISOTOPES
RADIOPHARMACEUTICALS
RADIUM 223
RADIUM 224
RADIUM 226
RECOMMENDATIONS
TERBIUM 149
TESTING
THORIUM 227
Alpha-Emitting
Radionuclides
cancer treatment
radiopharmaceuticals
Actinium-225
radium-223
bismuth-212
Alpha emitters